葛兰素史克与Syndivia达成药物开发和商业化权利协议

环球市场播报
Oct 27, 2025

  美股周一早盘,葛兰素史克(GSK)股价上涨1.9%,此前该公司宣布已与Syndivia达成协议,获得其用于转移性去势抵抗性前列腺癌(mCRPC)的临床前抗体药物偶联物(ADC)的全球独家开发和商业化权利,潜在里程碑付款最高达2.68亿英镑。该协议丰富了葛兰素史克的肿瘤管线,重点关注晚期前列腺癌治疗。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10